Innovotech Inc. Announces Amalgamation of Subsidiaries to Streamline Operations

(TheNewswire)

Innovotech Inc.

 

January 2, 2026 TheNewswire - Edmonton, Alberta Innovotech Inc. (TSXV: IOT or the "Company") is pleased to announce that effective January 1, 2026,  it has completed a horizontal short-form amalgamation pursuant to the Business Corporations Act (Alberta) whereby the Company's two wholly-owned subsidiaries Innovotech Labs Corporation and Keystone Labs Inc. have been amalgamated with the resulting amalgamated company continuing on as Innovotech Labs Corporation while maintaining the same articles, directors and officers as prior to the completion of the amalgamation.

 

By consolidating laboratory operations under the one entity of Innovotech Labs Corporation, the Company expects to streamline processes, reduce duplication and present an integrated and easier-to-navigate suite of laboratory services to its clients. The amalgamation also simplifies the Company's operating structure and reduces administrative and reporting complexity as the Company grows.  The timing of the amalgamation reflects management's assessment that the two laboratory businesses are operationally ready for consolidation and aligns with the start of the Company's fiscal year for accounting and reporting purposes.

 

"This amalgamation brings together the complementary expertise and resources of both laboratories to create a more agile and integrated organization," said Craig Milne, Chief Executive Officer of Innovotech Inc. "By operating as a single laboratory business, we are better positioned to serve clients efficiently, scale our services, drive innovation and pursue future growth."

 

The newly amalgamated Innovotech Labs Corporation will continue to operate under its high standards of quality and regulatory compliance, ensuring a seamless transition for clients and partners.

  

About Innovotech:

Innovotech Inc. is a Canadian boutique contract research organization specializing in advanced laboratory services and commercializing proprietary technologies. The Company provides expertise in antimicrobial testing, pharmaceutical analysis, and industrial laboratory solutions, supported by innovative methodologies and and products.  Innovotech Inc. serves clients across multiple sectors, delivering customized research and testing services designed to meet rigorous regulatory and scientific standards. Learn more at https://www.innovotech.ca.

 

Craig Milne, CEO           Innovotech Inc.

+1-604-239-1819        craig.milne@innovotech.ca

 

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward- looking statements, except as required by applicable law.

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

###

        

Copyright (c) 2026 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

IOT:CC
The Conversation (0)
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Interactive Chart

Latest Press Releases

Related News